{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T20:13:17Z","timestamp":1770408797395,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-36509-y","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:05:56Z","timestamp":1768460756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of RAS mutational status with clinical outcomes in metastatic colorectal cancer treated with trifluridine\/tipiracil or regorafenib"],"prefix":"10.1038","volume":"16","author":[{"given":"Meng-Che","family":"Hsieh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun-Ming","family":"Rau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuang-Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong-Chi","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-I","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Chiao","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Pao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"36509_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"36509_CR2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S2468-1253(21)00426-X","volume":"7","author":"SG Patel","year":"2022","unstructured":"Patel, S. G., Karlitz, J. J., Yen, T., Lieu, C. H. & CR, B. The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection. Lancet Gastroenterol. Hepatol. 7, 262\u2013274. https:\/\/doi.org\/10.1016\/S2468-1253(21)00426-X (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"36509_CR3","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M. & Wallace, M. B. Colorectal cancer. Lancet 394, 1467\u20131480. https:\/\/doi.org\/10.1016\/S0140-6736(19)32319-0 (2019).","journal-title":"Lancet"},{"key":"36509_CR4","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3748\/wjg.v29.i10.1569","volume":"29","author":"W Leowattana","year":"2023","unstructured":"Leowattana, W., Leowattana, P. & Leowattana, T. Systemic treatment for metastatic colorectal cancer. World J. Gastroenterol. 29, 1569\u20131588. https:\/\/doi.org\/10.3748\/wjg.v29.i10.1569 (2023).","journal-title":"World J. Gastroenterol."},{"key":"36509_CR5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller, L. H. & Schrag, D. Diagnosis and treatment of metastatic colorectal cancer: A review. JAMA 325, 669\u2013685. https:\/\/doi.org\/10.1001\/jama.2021.0106 (2021).","journal-title":"JAMA"},{"key":"36509_CR6","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2174\/1389450121999201117115717","volume":"22","author":"F Baidoun","year":"2021","unstructured":"Baidoun, F. et al. Colorectal cancer epidemiology: recent trends and impact on outcomes. Curr. Drug Targets. 22, 998\u20131009. https:\/\/doi.org\/10.2174\/1389450121999201117115717 (2021).","journal-title":"Curr. Drug Targets"},{"key":"36509_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12876-020-01464-z","volume":"20","author":"C Yu","year":"2020","unstructured":"Yu, C. & Zhang, Y. Establishment of prognostic nomogram for elderly colorectal cancer patients: a SEER database analysis. BMC Gastroenterol. 20, 347. https:\/\/doi.org\/10.1186\/s12876-020-01464-z (2020).","journal-title":"BMC Gastroenterol."},{"key":"36509_CR8","doi-asserted-by":"publisher","first-page":"175883592093608","DOI":"10.1177\/1758835920936089","volume":"12","author":"G Martini","year":"2020","unstructured":"Martini, G. et al. Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. Ther. Adv. Med. Oncol. 12, 1758835920936089. https:\/\/doi.org\/10.1177\/1758835920936089 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"36509_CR9","doi-asserted-by":"publisher","first-page":"5356","DOI":"10.3390\/curroncol28060447","volume":"28","author":"K Chen","year":"2021","unstructured":"Chen, K., Collins, G., Wang, H. & Toh, J. W. T. Pathological features and prognostication in colorectal cancer. Curr. Oncol. 28, 5356\u20135383. https:\/\/doi.org\/10.3390\/curroncol28060447 (2021).","journal-title":"Curr. Oncol."},{"key":"36509_CR10","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1053\/j.gastro.2023.04.029","volume":"165","author":"L Guo","year":"2023","unstructured":"Guo, L. et al. Molecular profiling provides clinical insights into targeted and immunotherapies as well as colorectal cancer prognosis. Gastroenterology 165, 414\u2013428. https:\/\/doi.org\/10.1053\/j.gastro.2023.04.029 (2023).","journal-title":"Gastroenterology"},{"key":"36509_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","volume":"20","author":"G Zhu","year":"2021","unstructured":"Zhu, G., Pei, L., Xia, H., Tang, Q. & Bi, F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol. Cancer 20, 143. https:\/\/doi.org\/10.1186\/s12943-021-01441-4 (2021).","journal-title":"Mol. Cancer"},{"key":"36509_CR12","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.7150\/ijbs.88779","volume":"20","author":"Y Zhou","year":"2024","unstructured":"Zhou, Y. et al. Impact of KRAS mutation on the tumor microenvironment in colorectal cancer. Int. J. Biol. Sci. 20, 1947\u20131964. https:\/\/doi.org\/10.7150\/ijbs.88779 (2024).","journal-title":"Int. J. Biol. Sci."},{"key":"36509_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41591-023-02240-8","volume":"29","author":"J van de Haar","year":"2023","unstructured":"van de Haar, J. et al. Codon-specific KRAS mutations predict survival benefit of trifluridine\/tipiracil in metastatic colorectal cancer. Nat. Med. 29, 605\u2013614. https:\/\/doi.org\/10.1038\/s41591-023-02240-8 (2023).","journal-title":"Nat. Med."},{"key":"36509_CR14","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager, G. W. et al. Trifluridine-Tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl. J. Med. 388, 1657\u20131667. https:\/\/doi.org\/10.1056\/NEJMoa2214963 (2023).","journal-title":"N Engl. J. Med."},{"key":"36509_CR15","doi-asserted-by":"publisher","first-page":"102945","DOI":"10.1016\/j.esmoop.2024.102945","volume":"9","author":"J Tabernero","year":"2024","unstructured":"Tabernero, J. et al. Impact of KRASG12 mutations on survival with trifluridine\/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial. ESMO Open. 9, 102945. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102945 (2024).","journal-title":"ESMO Open."},{"key":"36509_CR16","doi-asserted-by":"publisher","first-page":"e240029","DOI":"10.6004\/jnccn.2024.0029","volume":"22","author":"AB Benson","year":"2024","unstructured":"Benson, A. B. et al. Colon Cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc Netw. 22, e240029. https:\/\/doi.org\/10.6004\/jnccn.2024.0029 (2024).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"36509_CR17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/jnci\/djab190","volume":"114","author":"V Formica","year":"2022","unstructured":"Formica, V. et al. KRAS and BRAF mutations in stage II and III colon cancer: A systematic review and Meta-Analysis. J. Natl. Cancer Inst. 114, 517\u2013527. https:\/\/doi.org\/10.1093\/jnci\/djab190 (2022).","journal-title":"J. Natl. Cancer Inst."},{"key":"36509_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejca.2020.11.016","volume":"2021","author":"FA Sinicrope","year":"2020","unstructured":"Sinicrope, F. A. et al. Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. Eur. J. Cancer 2021, 101\u2013112. https:\/\/doi.org\/10.1016\/j.ejca.2020.11.016 (2020).","journal-title":"Eur. J. Cancer"},{"key":"36509_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12876-019-0965-5","volume":"19","author":"MZ Xie","year":"2019","unstructured":"Xie, M. Z., Li, J. L., Cai, Z. M., Li, K. Z. & Hu, B. L. Impact of primary colorectal cancer location on the KRAS status and its prognostic value. BMC Gastroenterol. 19, 46. https:\/\/doi.org\/10.1186\/s12876-019-0965-5 (2019).","journal-title":"BMC Gastroenterol."},{"key":"36509_CR20","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/annonc\/mdw261","volume":"27","author":"DP Modest","year":"2016","unstructured":"Modest, D. P. et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann. Oncol. 27, 1746\u20131753. https:\/\/doi.org\/10.1093\/annonc\/mdw261 (2016).","journal-title":"Ann. Oncol."},{"key":"36509_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes, A. et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 10\u201332. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003 (2023).","journal-title":"Ann. Oncol."},{"key":"36509_CR22","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.3390\/ijms25063304","volume":"25","author":"J Ros","year":"2024","unstructured":"Ros, J. et al. Targeting KRAS G12C mutation in colorectal Cancer, A review: new arrows in the quiver. Int. J. Mol. Sci. 25, 3304. https:\/\/doi.org\/10.3390\/ijms25063304 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"36509_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/oncolo\/oyac077","volume":"27","author":"M Fakih","year":"2022","unstructured":"Fakih, M. et al. Real-World study of characteristics and treatment outcomes among patients with KRAS p.G12C-Mutated or other KRAS mutated metastatic colorectal cancer. Oncologist 27, 663\u2013674. https:\/\/doi.org\/10.1093\/oncolo\/oyac077 (2022).","journal-title":"Oncologist"},{"key":"36509_CR24","doi-asserted-by":"publisher","first-page":"100567","DOI":"10.1016\/j.esmoop.2022.100567","volume":"7","author":"D Ciardiello","year":"2022","unstructured":"Ciardiello, D. et al. Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM). ESMO Open. 7, 100567. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100567 (2022).","journal-title":"ESMO Open."},{"key":"36509_CR25","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.2147\/CMAR.S174584","volume":"10","author":"D Chen","year":"2018","unstructured":"Chen, D. et al. Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis. Cancer Manag. Res. 10, 2915\u20132924 (2018).","journal-title":"Cancer Manag. Res."},{"key":"36509_CR26","doi-asserted-by":"publisher","first-page":"1252516","DOI":"10.3389\/fonc.2023.1252516","volume":"13","author":"L Qunaj","year":"2023","unstructured":"Qunaj, L., May, M. S., Neugut, A. I. & BO, H. Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer. Front. Oncol. 13, 1252516. https:\/\/doi.org\/10.3389\/fonc.2023.1252516 (2023).","journal-title":"Front. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36509-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36509-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36509-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T09:20:55Z","timestamp":1770369655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36509-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["36509"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-36509-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"24 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5294"}}